RecruitingPhase 1NCT07315113
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
Sponsor
Nuvectis Pharma, Inc.
Enrollment
18 participants
Start Date
Dec 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Provide written informed consent.
- years old or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
- Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.
Exclusion Criteria4
- Subject's cancer has a known oncogenic driver alteration other than EGFR.
- Known EGFR mutations that cause resistance to osimertinib
- Known human epidermal growth factor receptor 2 (HER2) overexpression
- Any contraindications to treatment with osimertinib
Interventions
DRUGNXP900
NXP900 is an orally administered inhibitor of SRC family kinases (SFK)
DRUGOsimertinib
Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07315113